Updates on RPE cell damage in diabetic retinopathy (Review)
Diabetic retinopathy (DR) is a microvascular complication of diabetes. The retinal pigment epithelium (RPE) forms the outer layer of the blood‑retinal barrier and serves a role in maintaining retinal function. RPE cell injury has been revealed in diabetic animal models, and high glucose (HG) levels may cause damage to RPE cells by increasing the levels of oxidative stress, promoting pro‑inflammatory gene expression, disrupting cell proliferation, inducing the endothelial‑mesenchymal transition, weakening tight conjunctions and elevating cell death mechanisms, such as apoptosis, ferroptosis and pyroptosis. Non‑coding RNAs including microRNAs, long non‑coding RNAs and circular RNAs participate in RPE cell damage caused by HG levels, which may provide targeted therapeutic strategies for the treatment of DR. Plant extracts such as citrusin and hesperidin, and a number of hypoglycemic drugs, such as sodium‑glucose co‑transporter 2 inhibitors, metformin and glucagon‑like peptide‑1 receptor agonists, exhibit potential RPE protective effects; however, the detailed mechanisms behind these effects remain to be fully elucidated. An in‑depth understanding of the contribution of the RPE to DR may provide novel perspectives and therapeutic targets for DR.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
---|---|
Enthalten in: |
Molecular medicine reports - 28(2023), 4 vom: 01. Okt. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Min [VerfasserIn] |
---|
Links: |
---|
Themen: |
Cell injury |
---|
Anmerkungen: |
Date Completed 21.08.2023 Date Revised 21.08.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.3892/mmr.2023.13072 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM360929311 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM360929311 | ||
003 | DE-627 | ||
005 | 20231226084052.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3892/mmr.2023.13072 |2 doi | |
028 | 5 | 2 | |a pubmed24n1203.xml |
035 | |a (DE-627)NLM360929311 | ||
035 | |a (NLM)37594078 | ||
035 | |a (PII)185 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Min |e verfasserin |4 aut | |
245 | 1 | 0 | |a Updates on RPE cell damage in diabetic retinopathy (Review) |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 21.08.2023 | ||
500 | |a Date Revised 21.08.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Diabetic retinopathy (DR) is a microvascular complication of diabetes. The retinal pigment epithelium (RPE) forms the outer layer of the blood‑retinal barrier and serves a role in maintaining retinal function. RPE cell injury has been revealed in diabetic animal models, and high glucose (HG) levels may cause damage to RPE cells by increasing the levels of oxidative stress, promoting pro‑inflammatory gene expression, disrupting cell proliferation, inducing the endothelial‑mesenchymal transition, weakening tight conjunctions and elevating cell death mechanisms, such as apoptosis, ferroptosis and pyroptosis. Non‑coding RNAs including microRNAs, long non‑coding RNAs and circular RNAs participate in RPE cell damage caused by HG levels, which may provide targeted therapeutic strategies for the treatment of DR. Plant extracts such as citrusin and hesperidin, and a number of hypoglycemic drugs, such as sodium‑glucose co‑transporter 2 inhibitors, metformin and glucagon‑like peptide‑1 receptor agonists, exhibit potential RPE protective effects; however, the detailed mechanisms behind these effects remain to be fully elucidated. An in‑depth understanding of the contribution of the RPE to DR may provide novel perspectives and therapeutic targets for DR | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a cell injury | |
650 | 4 | |a diabetic retinopathy | |
650 | 4 | |a drugs | |
650 | 4 | |a non‑coding RNAs | |
650 | 4 | |a retinal pigment epithelium cell | |
650 | 7 | |a Hypoglycemic Agents |2 NLM | |
650 | 7 | |a Glucose |2 NLM | |
650 | 7 | |a IY9XDZ35W2 |2 NLM | |
700 | 1 | |a Tian, Meimei |e verfasserin |4 aut | |
700 | 1 | |a Wang, Yuling |e verfasserin |4 aut | |
700 | 1 | |a Ma, Huijie |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Yaru |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Xinli |e verfasserin |4 aut | |
700 | 1 | |a Liu, Yan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Molecular medicine reports |d 2008 |g 28(2023), 4 vom: 01. Okt. |w (DE-627)NLM192195727 |x 1791-3004 |7 nnns |
773 | 1 | 8 | |g volume:28 |g year:2023 |g number:4 |g day:01 |g month:10 |
856 | 4 | 0 | |u http://dx.doi.org/10.3892/mmr.2023.13072 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 28 |j 2023 |e 4 |b 01 |c 10 |